Phase II clinical trial - Gynécologie - Ovaires

RAMP-201 (VS-6766-201 / ENGOT-ov60)
Gynécologie - Ovaires
Ouvert depuis le: 12.04.2023
Site: Paris
Public cible
A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Description de l'essai
This study will assess the safety and efficacy of VS-6766 monotherapy and in combination with Defactinib in subjects with recurrent Low-Grade Serous Ovarian Cancer (LGSOC)